MCM
ALXN

Manchester Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Manchester Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4
Closed -$1K – 826
2020
Q4 		$1K Buy
+4
New +$514 ﹤0.01% 719
2015
Q1 		– Sell
-169
Closed -$31K – 952
2014
Q4 		$31K Hold
169
– – ﹤0.01% 822
2014
Q3 		$28K Hold
169
– – ﹤0.01% 837
2014
Q2 		$26K Hold
169
– – ﹤0.01% 830
2014
Q1 		$26K Buy
+169
New +$26.9K ﹤0.01% 735
2013
Q4 		– Sell
-169
Closed -$20K – 974
2013
Q3 		$20K Hold
169
– – ﹤0.01% 744
2013
Q2 		$16K Buy
+169
New +$16.3K ﹤0.01% 783

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Manchester Capital Management's ALXN Position: Q1 2021 in Review

Manchester Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 4 shares — an estimated $1K sold.

Manchester Capital Management first reported a position in ALXN in Q2 2013 and held it in 7 quarters. The position peaked at $31K in Q4 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Manchester Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Manchester Capital Management sold 4 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1K.
  • Manchester Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Manchester Capital Management's Alexion Pharmaceuticals position peaked at $31K in Q4 2014.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Manchester Capital Management's 13F filing for Q1 2021, filed 13 May 2021.